Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target
Severe COVID-19 is characterized by acute respiratory distress syndrome (ARDS)-like hyperinflammation and endothelial dysfunction, that can lead to respiratory and multi organ failure and death. Interstitial lung diseases (ILD) and pulmonary fibrosis confer an increased risk for severe disease, whil...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.687397/full |
| _version_ | 1819122061595901952 |
|---|---|
| author | Konstantinos Ntatsoulis Theodoros Karampitsakos Eliza Tsitoura Elli-Anna Stylianaki Alexios N. Matralis Argyrios Tzouvelekis Katerina Antoniou Vassilis Aidinis |
| author_facet | Konstantinos Ntatsoulis Theodoros Karampitsakos Eliza Tsitoura Elli-Anna Stylianaki Alexios N. Matralis Argyrios Tzouvelekis Katerina Antoniou Vassilis Aidinis |
| author_sort | Konstantinos Ntatsoulis |
| collection | DOAJ |
| description | Severe COVID-19 is characterized by acute respiratory distress syndrome (ARDS)-like hyperinflammation and endothelial dysfunction, that can lead to respiratory and multi organ failure and death. Interstitial lung diseases (ILD) and pulmonary fibrosis confer an increased risk for severe disease, while a subset of COVID-19-related ARDS surviving patients will develop a fibroproliferative response that can persist post hospitalization. Autotaxin (ATX) is a secreted lysophospholipase D, largely responsible for the extracellular production of lysophosphatidic acid (LPA), a pleiotropic signaling lysophospholipid with multiple effects in pulmonary and immune cells. In this review, we discuss the similarities of COVID-19, ARDS and ILDs, and suggest ATX as a possible pathologic link and a potential common therapeutic target. |
| first_indexed | 2024-12-22T06:46:28Z |
| format | Article |
| id | doaj.art-8e5bc9975668472b992f6d1527241851 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-22T06:46:28Z |
| publishDate | 2021-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-8e5bc9975668472b992f6d15272418512022-12-21T18:35:16ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-10-011210.3389/fimmu.2021.687397687397Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic TargetKonstantinos Ntatsoulis0Theodoros Karampitsakos1Eliza Tsitoura2Elli-Anna Stylianaki3Alexios N. Matralis4Argyrios Tzouvelekis5Katerina Antoniou6Vassilis Aidinis7Institute of Bio-Innovation, Biomedical Sciences Research Center Alexander Fleming, Athens, GreeceDepartment of Respiratory Medicine, School of Medicine, University of Patras, Patras, GreeceLaboratory of Molecular & Cellular Pneumonology, Department of Respiratory Medicine, School of Medicine, University of Crete, Heraklion, GreeceInstitute of Bio-Innovation, Biomedical Sciences Research Center Alexander Fleming, Athens, GreeceInstitute of Bio-Innovation, Biomedical Sciences Research Center Alexander Fleming, Athens, GreeceDepartment of Respiratory Medicine, School of Medicine, University of Patras, Patras, GreeceLaboratory of Molecular & Cellular Pneumonology, Department of Respiratory Medicine, School of Medicine, University of Crete, Heraklion, GreeceInstitute of Bio-Innovation, Biomedical Sciences Research Center Alexander Fleming, Athens, GreeceSevere COVID-19 is characterized by acute respiratory distress syndrome (ARDS)-like hyperinflammation and endothelial dysfunction, that can lead to respiratory and multi organ failure and death. Interstitial lung diseases (ILD) and pulmonary fibrosis confer an increased risk for severe disease, while a subset of COVID-19-related ARDS surviving patients will develop a fibroproliferative response that can persist post hospitalization. Autotaxin (ATX) is a secreted lysophospholipase D, largely responsible for the extracellular production of lysophosphatidic acid (LPA), a pleiotropic signaling lysophospholipid with multiple effects in pulmonary and immune cells. In this review, we discuss the similarities of COVID-19, ARDS and ILDs, and suggest ATX as a possible pathologic link and a potential common therapeutic target.https://www.frontiersin.org/articles/10.3389/fimmu.2021.687397/fullCOVID-19ARDSpulmonary fibrosisAutotaxinlysophosphatidic acid |
| spellingShingle | Konstantinos Ntatsoulis Theodoros Karampitsakos Eliza Tsitoura Elli-Anna Stylianaki Alexios N. Matralis Argyrios Tzouvelekis Katerina Antoniou Vassilis Aidinis Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target Frontiers in Immunology COVID-19 ARDS pulmonary fibrosis Autotaxin lysophosphatidic acid |
| title | Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target |
| title_full | Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target |
| title_fullStr | Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target |
| title_full_unstemmed | Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target |
| title_short | Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target |
| title_sort | commonalities between ards pulmonary fibrosis and covid 19 the potential of autotaxin as a therapeutic target |
| topic | COVID-19 ARDS pulmonary fibrosis Autotaxin lysophosphatidic acid |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.687397/full |
| work_keys_str_mv | AT konstantinosntatsoulis commonalitiesbetweenardspulmonaryfibrosisandcovid19thepotentialofautotaxinasatherapeutictarget AT theodoroskarampitsakos commonalitiesbetweenardspulmonaryfibrosisandcovid19thepotentialofautotaxinasatherapeutictarget AT elizatsitoura commonalitiesbetweenardspulmonaryfibrosisandcovid19thepotentialofautotaxinasatherapeutictarget AT elliannastylianaki commonalitiesbetweenardspulmonaryfibrosisandcovid19thepotentialofautotaxinasatherapeutictarget AT alexiosnmatralis commonalitiesbetweenardspulmonaryfibrosisandcovid19thepotentialofautotaxinasatherapeutictarget AT argyriostzouvelekis commonalitiesbetweenardspulmonaryfibrosisandcovid19thepotentialofautotaxinasatherapeutictarget AT katerinaantoniou commonalitiesbetweenardspulmonaryfibrosisandcovid19thepotentialofautotaxinasatherapeutictarget AT vassilisaidinis commonalitiesbetweenardspulmonaryfibrosisandcovid19thepotentialofautotaxinasatherapeutictarget |